Long-Term safety check: does a pioneering cancer treatment carry a hidden risk?
NCT ID NCT07378969
Summary
This study aims to understand if a specific CAR-T cell therapy (tisagenlecleucel) could be linked to patients developing a second, different type of T-cell cancer later on. It will analyze existing tissue and blood samples from about 30 people who received the therapy and were later diagnosed with a secondary T-cell cancer. The goal is to gather safety knowledge, not to provide a new treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY MALIGNANCIES OF T-CELL ORIGIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.